Elexacaftor-tezacaftor-ivacaftor combination therapy shows no clinically meaningful improvement in bone health or calcium metabolism in patients with cystic fibrosis, a Danish study shows.

BOSTON--(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration's Pulmonary Allergy Drugs Advisory Committee (PADAC) voted 13-2 ...

Please provide your email address to receive an email when new articles are posted on . Patients with cystic fibrosis with CFTR gating mutations aged 6 years and older treated with ivacaftor had lower ...

Data from a phase 3 trial are supporting the use of tezacaftor in combination with ivacaftor for the treatment of cystic fibrosis (CF) in children aged 6 to 11 years, finding that the treatment ...

- For the first time, approximately 6,000 patients with one minimal function mutation and one F508del mutation have a medicine to treat the underlying cause of their disease– -12,000 people with one ...

Review the side-effects of Ivacaftor as documented in medical literature. The term "side effects" refers to unintended effects that can occur as a result of taking the medication. In majority of the ...

While the findings of Lisa Feng and coauthors (May 2018) regarding the impact of ivacaftor on cystic fibrosis–related hospitalizations are encouraging, we are concerned about two methodological study ...

• Tezacaftor and ivacaftor are available as tablets and should be taken by mouth. • Take the tablets with fatty foods such as whole milk, cheese, butter, cheese pizza, yogurt, or eggs for better ...

The oral drug ivacaftor appears to be safe and could be beneficial to young children between the ages of 2 and 5 with a specific type of cystic fibrosis, according to new research published in The ...

All her life, Lindsay Shipp knew that she was dying. As a baby, she would cry after eating, and salt collected on her forehead. The diagnosis was cystic fibrosis, an incurable genetic disease that, at ...

Please provide your email address to receive an email when new articles are posted on . The FDA has approved ivacaftor for the treatment of cystic fibrosis in infants as young as 4 months old with at ...